Jeffrey Klausner
Infectious Disease · Los Angeles, CANPI 1508973249
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.1%), grants and speaking fees — rather than concentrated in one kind of arrangement. Cepheid accounts for 64.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $69,418 and has fallen 95.2% since, to $3,306 in 2025. Among infectious disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 49 payments — averaging $2577.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cepheid$82K
- GSK$13K
- Paratek Pharmaceuticals, Inc.$7K
- Roche Diagnostics Corporation$6K
- Abbott$6K
- Visby Medical, Inc.$6K
- plus $6K from 5 others
Across 58 payments — averaging $17,887 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$430K
- Gen-probe, Inc.$199K
- Cepheid$173K
- GSK$118K
- AbbVie$117K
What the payments were for
- Consulting fees$54,42343%
- Speaking & faculty fees$14,23011%
- Grants$54,00043%
- Travel & lodging$2,6082%
- Food & beverage$1,0081%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cepheid | 15 | $81,955 |
| GSK | 2 | $13,308 |
| Paratek Pharmaceuticals, Inc. | 2 | $7,219 |
| Roche Diagnostics Corporation | 2 | $6,400 |
| Abbott | 2 | $6,000 |
| Visby Medical, Inc. | 8 | $5,853 |
| Biofire Diagnostics, LLC | 4 | $2,850 |
| Roche Diagnostics International Ltd | 1 | $1,497 |
| La Jolla Pharmaceutical Company | 3 | $702 |
| AbbVie | 6 | $394 |
| Gilead | 4 | $111 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENEXPERT$21,338
- NUZYRA$7,219
- Visby Medical Sexual Health Click Test$5,738
- ID NOW INSTRUMENT$3,750
- cobas 4800 CTNG Test v20$3,500
- Visby Medical Respiratory Health Test$3,188
- MD cobas Instruments and Reagents$2,900
- BIOFIRE RESPIRATORY PANEL 2.1$1,600
- XPERT C. DIFFICILE$750
- BioFire FilmArray$400
How this compares
$126,289 in reported general payments places this provider in the 95th percentile of 856 infectious disease providers in California.
Other infectious disease in Los Angeles
- Jay GladsteinLos Angeles$657K
- Otto YangLos Angeles$472K
- Irving PosalskiLos Angeles$234K
- Peter RuaneLos Angeles$174K
- Raphael LandovitzLos Angeles$147K
- Harold Glenn San AgustinLos Angeles$82K
- Fred SattlerLos Angeles$63K
- Judith CurrierLos Angeles$32K
- David HaakeLos Angeles$30K
- Christopher FoltzLos Angeles$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.